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INTRODUCTION
Tuberculous meningitis  is  the most  dangerous form of infection with  Mycobacterium tuberculosis.  
Despite chemotherapy, it is fatal in 25% of adults and causes neurological sequelae in 25% of survivors 
[1].   Delay in  diagnosis  and  treatment  are  regarded  as  the  major  contributing  factors  in  the  high 
mortality.  The diagnosis and treatment of tuberculous meningitis continues to challenge physicians 
throughout the world.
Commencing treatment for tuberculous meningitis prior to the onset of alteration of sensorium is the 
only way to  ensure  improved  outcome.  Unfortunately,  three  factors  make  this  difficult.  First,  the 
presenting clinical features of the disease are non-specific. Second, small numbers of bacilli  in the 
cerebrospinal  fluid  (CSF)  reduce  the  sensitivity  of  conventional  bacteriology.  Third,  alternative 
diagnostic methods are incompletely assessed [2].
The current practice for diagnosis of tuberculous meningitis is based on clinical features (including 
CSF analysis), radiology, bacteriology and molecular methods.  Several diagnostic criteria are in use 
for initiating antituberculous therapy. There are problems with these criteria. First,  the criteria vary 
according to the prevalence of tuberculosis. Second, if antituberculous chemotherapy is started on the 
basis of one diagnostic variable, more than half will be wrongly treated unnecessarily exposing them to 
the risks of drug toxicity. If treatment is only begun in the presence of more than one variable, nearly 
half will not receive appropriate treatment and these patients will eventually die or be left with severe 
neurological sequelae. 
The definitive diagnosis of tuberculous meningitis depends upon the detection of the tubercle bacilli in 
the CSF, either by smear examination or by bacterial culture. Kennedy and Fallon [3] reported tubercle 
bacilli  in  87% of  clinically  suspected  cases.  This  requires  large  volumes  of  CSF  to  be  carefully 
examined. However, reports from developing countries could achieve bacteriological confirmation in 
as few as 10% of the cases. Culture of the CSF for tubercle bacilli is not invariably positive. It requires 
several weeks before culture is positive for mycobacterium bacilli. 
Because of frequent difficulty in detecting tubercle bacilli in smears or cultures of CSF, a number of 
tests have been developed to establish early and definitive diagnosis. 
Radioactive bromide partition test and identification of components of the mycobacterial cell wall (e.g., 
tuberculostearic acid) have been reported to have sensitivity and specificity of over 90%. However, the 
clinical utility of these has not been found to be satisfactory [4]. 
Antibodies against tubercle bacilli can be detected with enzyme-linked immunosorbent assay (ELISA) 
with variable success.
The latex particle agglutination test, which allows rapid detection of tubercle bacillus antigen in CSF, 
has been reported to be a simple and specific test. 
The intradermal  tuberculin  skin test  (TST) is  helpful  when positive.  This  has been reported to  be 
negative initially in 50-70% of cases and often becomes positive during therapy. 
Mycobacterial RNA or DNA sequences in CSF are identified using cDNA probes by the polymerase 
chain reactions. These are highly specific and sensitive in the diagnosis of tuberculous meningitis.   
Recent advances in M. tuberculosis genomics, using subtractive hybridization and DNA microarrays, 
have identified a genomic segment, RD1, that is present in M. tuberculosis complex but absent from all 
strains of M. bovis BCG and almost all environmental mycobacteria [5].  RD1 gene products offer the 
potential for the development of new diagnostic tests that might differentiate  M.tuberculosis (MTB) 
infection from BCG vaccination and exposure to environmental mycobacteria. Early secretory antigen 
target – 6 (ESAT-6) and culture filtrate protein 10 (CFP 10) are two such gene products [6].  
The enzyme-linked immunospot assay (ELISPOT) detects  interferon-γ (IFN-γ) secreting T cells 
specific  for  these  two  antigens  [7].  Applied  to  blood samples  this  assay  has  high  sensitivity  and 
specificity  for  the  diagnosis  of  tuberculous  infection,  but  does  not  distinguish  between  latent 
tuberculous infection and active tuberculosis[8]. Recently it has been shown that ESAT-6-specific IFN-
γ-secreting CD4+ T cells are concentrated at sites of active tuberculosis [9]. Using ELISPOT these cells 
can be detected in pleural fluid, suggesting that this assay may be a rapid, sensitive and specific marker 
for active tuberculosis  at  specific anatomical sites. However,  detection of functional MTB-antigen-
specific T cells in CSF is scientifically challenging given the rapid activation-induced death of CSF T 
cells in tuberculous meningitis.
Given the possibility of using this T cell assay for diagnosis of active tuberculous infection, we aimed 
to determine whether IFN-γ-secreting MTB-antigen-specific T cells are present in the CSF of patients 
with tuberculous meningitis, whether the use of ELISPOT on CSF samples is feasible, and whether 
ELISPOT has a clinically useful diagnostic sensitivity for active tuberculous meningitis.
AIM
To determine  the  presence of  interferon γ-secreting  Mycobacterium tuberculous antigen-specific  T 
cells  in  the  cerebrospinal  fluid  of  patients  with  tuberculous  meningitis  using  the  enzyme  linked 
immunospot assay (ELISPOT).
OBJECTIVES
To evaluate usefulness of the enzyme linked immunospot assay (ELISPOT), a T cell based assay using 
specific  Mycobacterium tuberculosis antigens, ESAT-6 and CFP 10, for the diagnosis of tuberculous 
meningitis.
LITERATURE REVIEW
Historical background
Tuberculosis has stalked humankind for centuries. The characteristic lesions caused by the rod-like 
tubercle bacillus  Mycobacterium tuberculosis have been discovered in Neolithic skeletons in Europe, 
and in Egypt in mummies dating back to 3700 BC. Pulmonary tuberculosis, or ‘leprosy of the lung’, 
was described and known as phthisis by Hippocrates [10].  At the height of the tubercular epidemic of 
1882, the self trained Prussian bacteriologist, Robert Koch isolated and identified the tubercle bacillus, 
thereby proving the contagious nature of the disease [11].  In 1933, Rich and McCordock, after a series 
of post-mortem experiments in rabbits and children, found that tubercular meningitis developed after 
the release of bacilli from old focal lesions in communication with the meninges [12]. 
The only treatment for tuberculosis then was a long stay in a sanatorium with complete rest, nutritious 
diet and fresh air. Despite the discovery of the BCG (Bacilli-Calmette-Guerin) in 1906, there was no 
cure for  tuberculosis  until  the introduction of streptomycin in  the late  1940s.  Despite  advances in 
recognition  of  the  disease,  improved  living  conditions  and  effective  chemotherapeutic  drugs, 
tuberculosis continues to manifest in humans in different forms.
Epidemiology
Tuberculosis is the world’s second commonest cause of death from infectious disease, after HIV/AIDS. 
There were an estimated 8 – 9 million new cases of tuberculosis in 2000, fewer than half of which were 
reported; 3 – 4 million cases were sputum – smear positive, the most infectious form of the disease 
[13]. Sub-Saharan Africa has the highest incidence rate (290 per 100 000 population), but the most 
populous countries of Asia have the largest number of cases: India, China, Indonesia, Bangladesh and 
Pakistan together account for more than half the global burden. The average prevalence of all forms of 
tuberculosis in India is estimated to be 5.05 per thousand, prevalence of smear-positive cases being 
2.27 per thousand and average annual incidence of smear –positive cases 84 per 1,00,000 annually 
[14].  It  has  been  estimated  that  approximately  10%  of  all  patients  with  tuberculosis  have  CNS 
involvement. Tuberculous meningitis accounts for 70 to 80% of cases of neurological tuberculosis [15]. 
Pathology and Pathogenesis of tuberculous meningitis
The macroscopic consequences of infection have been researched post mortem and, more recently, 
through CT and MRI of the brain [16]. The early meningeal exudate setting off the whole process of 
basal tuberculous meningitis is believed to arise from outward extension of a small focus in the cortical 
surface, often referred to as the ‘Rich focus’. Alternatively, there may be miliary TB of the brain, and 
one of the miliary tubercles may rupture outwards to produce similar extensive meningitis. 
In summary, three processes cause most of the common neurological deficits: the adhesive exudates 
can obstruct CSF causing hydrocephalus and compromise cranial nerves; granulomas can coalesce to 
form  tuberculomas  (or  an  abscess)  which,  depending  on  their  location,  cause  diverse  clinical 
consequences; and an obliterative vasculitis can cause infarction and stroke syndromes [2].  
Molecular and Cellular pathogenesis
The main route of entry of the causative agent is the respiratory route and hence alveolar macrophages 
are  the  important  cell  types,  which  combat  the  pathogen.  M  tuberculosis replicates  slowly  but 
continuously  and  spreads  via  the  lymphatic  system  to  the  hilar  lymph  nodes.  In  most  infected 
individuals, cell-mediated immunity develops 2 to 8 weeks after infection. Activated T lymphocytes 
and  macrophages  form  granulomas  that  limit  further  replication  and  spread  of  the  organism.  M 
tuberculosis is in the centre of these caseating granulomas, but is usually not viable.  Unless there is 
subsequent  defect  in cell-mediated immunity,  the infection generally remains contained and active 
disease may never occur [17]. 
The development of cell-mediated immunity against M tuberculosis is associated with the development 
of a positive result in the tuberculin skin test. At the cellular level, an effective host immune response 
occurs  as  follows  [18].  Alveolar  macrophages  infected  with  M  tuberculosis interact  with  T 
lymphocytes via several important cytokines. The infected macrophage releases interleukins 12 and 18, 
which stimulate T lymphocytes (predominantly CD4 positive T lymphocytes) to release interferon γ. 
This cytokine, in turn, stimulates the phagocytosis of M tuberculosis in the macrophage. Interferon γ 
does not directly stimulate the killing of M tuberculosis by the macrophage, at least partly because the 
organism inhibits the cytokine’s transcriptional responses.   Interferon γ is, however, crucial for the 
control of M tuberculosis infection, and it also stimulates the macrophage to release tumour necrosis 
factor  α, which is important in granuloma formation and control of the extent of infection. The T-
lymphocyte response is antigen specific and is influenced by the major histocompatibility complex. 
Kinetics of immune response is used to understand the pathophysiology and prognosis of patients with 
tuberculous meningitis [56]. CSF concentrations of lactate, interleukin-8, and interferon γ were high 
before treatment and then decreased rapidly with antituberculosis chemotherapy. However, significant 
immune activation and blood-brain barrier dysfunction were still apparent after 60 days of treatment. 
Death was associated with high initial CSF concentrations of lactate, low numbers of white blood cells, 
in particular neutrophils, and low CSF glucose levels.   
Several factors trigger subsequent development of active disease. HIV is the greatest single risk factor 
for progression to active disease in adults. Other medical conditions that can compromise the immune 
system and predispose to development of active disease include poorly controlled diabetes mellitus, 
renal  failure,  underlying  malignant  disease,  chemotherapy,  extensive  corticosteroid  therapy, 
malnutrition, and deficiency of vitamin D or A. These conditions cause defects in the production of 
tumour necrosis factor α, interferon γ, and interferon γ receptor and interleukin-12 receptor β1.
Clinical diagnosis
Udani et al, in their report, have described the various neurological syndromes caused by tuberculosis 
[19]. A high index of clinical suspicion is needed to diagnose tuberculous meningitis, as the initial 
symptoms may be non-specific. Non-specific symptoms include malaise, anorexia, fatigue, fever, and 
headache.  These may last 2-8 weeks prior to the development of meningeal irritation. This is then 
followed by appearance of focal neurological deficits. As the disease progresses, increasing evidence of 
cerebral dysfunction sets in with apathy and irritability progressing to increasing lethargy, confusion, 
stupor and coma. The terminal illness is characterized by deep coma with decerebrate or decorticate 
rigidity. The Medical Research Council clinical staging for tuberculous meningitis is as follows [20]:
Stage I: prodromal phase with no definite neurological symptoms
Stage II: signs of meningeal irritation with slight or no clouding of sensorium and minor (cranial nerve 
palsies), or no neurological deficit
Stage  III:  severe  clouding  of  sensorium,  convulsions,  focal  neurological  deficit  and  involuntary 
movements 
The single most important determinant of outcome, for both survival and sequelae,  is the stage of 
tuberculous meningitis at which treatment has been started. If treatment is started in stage I, mortality 
and morbidity is very low, while in stage III almost 50% of patients die, and those who recover may 
have some form of neurological sequelae. 
CSF analysis  is an important aspect in the diagnosis of tuberculous meningitis.  Usually,  there is a 
predominant lymphocytic reaction (60 –400 white cell per ml) with raised protein levels (0.8 – 4 g/l). 
In the early stages of infection, a significant number of polymorphonuclear cells may be observed, but 
over the course of several days to weeks they are typically replaced by lymphocytes. There is a gradual 
decrease in the sugar  concentration of the CSF, which is  usually less than 50% of serum glucose 
concentration, the value ranging from 18 – 45 mg/dl [21].    
Chest  radiography  finds  active  or  previous  tuberculosis  infection  in  about  50%  of  those  with 
tuberculous  meningitis,  but  these  findings  lack  specificity  in  settings  with  a  high  prevalence  of 
pulmonary tuberculosis.
Two studies have tried to identify the clinical and CSF findings predictive of tuberculous meningitis. 
The first by Kumar et al compared clinical findings at presentation of 110 children with tuberculous 
meningitis  with  94  children  who  had  meningitis  which  was  pyogenic  or  who  recovered  with  no 
antituberculous treatment.  Five clinical variables were predictive of tuberculous meningitis: report of 
symptoms for longer than 6 days, optic atrophy, focal neurological deficit, abnormal movements, and 
neutrophils forming less than half the total CSF leucocytes [22].  
The second study by Thwaites et al compared the clinical outcomes of 143 Vietnamese adults with 
tuberculous meningitis (TM) with 108 who had either a pathogenic bacteria isolated from the CSF or a 
CSF glucose to blood glucose ratio less than 0.5 and recovered without antituberculous treatment[23]. 
A diagnostic rule was developed based on five variables that had a sensitivity of 86% and specificity of 
79% when it was tested on a further 75 adults.
Variable Score
Age (years)
>36
<36
2
0
Blood WCC (per ml)
>15000
<15000
4
0
History of illness (days)
≥6
<6
-5
0
CSF total WCC (per ml)
≥750
<750
3
0
CSF % neutrophils
≥90
<90
4
0
WCC = white cell count. Suggested rule for diagnosis: total score ≤ 4 = TM; total score >4 = non –TM 
(TM – tuberculous meningitis)
The results of these two diagnostic rules are affected by tuberculosis and HIV infection prevalence. 
Given  the  fatal  consequences  of  delayed  treatment,  clinicians  should  be  encouraged  to  initiate 
“empirical therapy” in the setting of compatible clinical, epidemiological and laboratory findings.
Radiological diagnosis
Computed tomography (CT) or magnetic resonance imaging (MRI) of the brain may reveal thickening 
and intense enhancement of meninges, especially in basilar regions [24]. Ventricular enlargement is 
present in majority of patients. The reported frequency of infarcts demonstrated by CT varies from 
20.5% to 38%. Davis et al found tuberculomas in 16% of patients with culture positive or presumptive 
tuberculous  meningitis  [25].  It  is  difficult  to  differentiate  forms  of  neurotuberculosis  from  other 
cerebral disorders radiologically. Kumar et al compared the CT scans of 94 children with tuberculous 
meningitis  with  those  of  52  children  with  pyogenic  meningitis  and  found  basal  enhancement, 
hydrocephalus,  tuberculoma  and  infarction  more  common  in  those  with  tuberculous  meningitis, 
whereas  subdural  collections  were  more  common  in  those  with  pyogenic  meningitis  [26].  They 
suggested basal meningeal enhancement, tuberculoma, or both, were 89% sensitive and 100% specific 
for the diagnosis of tuberculous meningitis.  Cranial MRI is better than CT for showing brain stem and 
cerebellar pathology, tuberculomas, infarcts, and the extent of inflammatory exudates.  
Tests for detection and identification of mycobacteria
They are  broadly divided into direct  and indirect  tests.  The direct  approach is  concerned with the 
detection of the mycobacteria by microscopy or culture, detection of tuberculostearic acid (TSBA), 
biochemical assays, mycobacterial antigen assays and identification of mycobacteria by nucleic acid 
amplification techniques.  The indirect approach includes measurements of host immunity against the 
bacteria: humoral immunity via the detection of antibodies against the bacteria and cellular immunity 
via skin tests and T cell based assays.
DIRECT TESTS
Microscopy
Microscopy using Zeihl-Neelsen method or flurochrome procedures with stains such as auramine / 
rhodamine  is  rapid,  cheap  and  easy.  Sensitivity  depends  on  the  source  of  the  sample.  The 
demonstration of AFB in CSF in patients with tuberculous meningitis is less than 20%. A recent study 
reported a bacteriological diagnosis  of tuberculous meningitis in 107 (81%) of 132 adults with the 
disease; acid-fast bacilli were seen in 77 (58%) patients, and cultured from 94 (71%) patients [27]. 
They recommend that at least 6 ml of CSF should be collected and examined for 30 minutes to improve 
the yield.   
Detection of TSBA
Tuberculostearic acid (TSBA) is a cell wall fatty acid of mycobacteria and can be detected with gas 
chromatography. This was reported as a rapid diagnostic test for tuberculous meningitis. It is however, 
impractical for average routine laboratory because of the equipment and skill needed for the test [28].
Antigen detection
Mycobacterial antigens have been detected by enzyme linked immunosorbent assay (ELISA) in sputum 
and CSF [29] and by latex agglutination assay in CSF [30].  
Culture
Culture for Mycobacterium tuberculosis is considered the gold standard in the diagnosis of tuberculosis 
[31].  Decontamination  procedures  needed  for  pulmonary,  urinary  and  gastric  juice  sample  is 
unnecessary for CSF and other materials collected aseptically, which can be inoculated directly on the 
media. The recommended practice is to culture on both liquid and solid media. Solid media include egg 
based media such as Lowenstein-Jensen, Coletsos or agar based media such as Middlebrook 7H10. 
Liquid media include Kirchner or Middlebrook 7H9 broth. A mean incubation period of 4 weeks is 
needed before growth can be detected. There are three rapid culture methods, where growth can be 
picked up in 2 to  3 weeks,  these include the radiometric  BACTEC method, Septi  Chek AFB and 
microcolony detection on solid media.  
Nucleic acid amplification
Nucleic acid (DNA or RNA) amplification techniques can detect and identify mycobacteria directly in 
clinical samples. The most widely studied is the polymerase chain reaction (PCR). These PCR assays 
may target either DNA or rRNA and these could be based on conventional DNA based PCR, nested 
PCR and RT-PCR. Targets include insertion and repetitive elements, various protein encoding genes 
and ribosomal RNA [32]. A recent systematic review and meta-analysis calculated that the sensitivity 
and  specificity  of  commercial  nucleic-acid-amplification  assays  for  the  diagnosis  of  tuberculous 
meningitis was 56% (95% CI 46-66) and 98% (97-99) respectively [33]. According to this data, the 
sensitivity of these assays is too low and may not be better than bacteriology.  
INDIRECT TESTS
Antibody detection
These tests  use various modifications of the ELISA or immunochromatographic methods to  detect 
different antibody classes. The commonly evaluated tests are based on the detection of IgG or IgA 
against 38 k Da protein either in the pure or recombinant form. An ELISA test using mycobacterial 
antigens was devised in this institution. The assay detected mycobacterial antibodies in the CSF of 
patients with tuberculous meningitis. Three antigens namely PPD, BCG, and M tuberculosis were used. 
With the M.tuberculosis antigen, the sensitivity of the assay was 72% and specificity 92% [34].  
Tests based on cellular immunity
1.Tuberculin skin test
Since M. tuberculosis is an intracellular pathogen, assessment of whether a patient’s T cells have been 
exposed to, and sensitized by, antigens specific to M tuberculosis provides an alternative approach to 
diagnosis and is the principle upon which the classic tuberculin skin test (TST) is based. TST involves 
intradermal inoculation of purified protein derivative (PPD), a crude precipitate of  M. tuberculosis  
culture supernatant that contains more than 200 antigens widely shared among mycobacteria other than 
M.tuberculosis,  including  M.bovis  bacille  Calmette-Guerin  (BCG)  and  many  environmental 
mycobacteria  [35].  It  elicits  a  delayed-type hypersensitivity response in sensitized individuals.  The 
broad antigenic  cross-reactivity of  PPD is  responsible  for  the  poor  specificity of  TST.  A positive 
reaction  is  consistent  with  BCG  vaccination,  exposure  to  environmental  mycobacteria,  or  M. 
tuberculosis infection.  Repeated  inoculation  of  tuberculin  can  itself  boost  a  delayed-type 
hypersensitivity response to PPD; this booster effect is another cause of false-positive TST reactions. 
The intrinsic sensitivity of the TST for detecting latent M.tuberculosis infection is not known, because 
there is no definitive test against which to compare it; however, for patients with active tuberculosis, it 
is 75% -90% sensitive, and its sensitivity falls to <50% in patients with disseminated disease [36]. 
The tuberculin  gamma interferon  assay,  QuantiFERON-TB (QIFN),  is  an  in  vitro  test  of  cell-
mediated  immunity [37].   Sensitivity  was  not  significantly  different  for  smear-negative  or  smear-
positive cases (80% versus 71%). The QIFN assay is a potential replacement for the Mantoux test.
2. T cell based assay
ELISPOT IN THE DIAGNOSIS OF TUBERCULOUS MENINGITIS
Many attempts have been made to identify and isolate specific antigens from 
M tuberculosis for use as diagnostic reagents. The identification of regions in the 
M tuberculosis genomes that are absent in BCG and most non-tuberculous mycobacteria provide an 
opportunity to develop new specific diagnostic tools by rational design. The test used here is an ex-vivo 
enzyme linked immunospot (ELISPOT) assay for IFN-γ. The basic principle of the test is the same as 
for the tuberculin skin test. In the in-vitro diagnostic test, mononuclear cells from the site of infection 
are  stimulated  in  vitro  and  production  of  IFN-γ from  sensitized  T  cells  is  measured  by  ELISA 
technique.  The  only  difference  being  that  while  in  the  TST,  sensitization  to  several  common 
mycobacterial  antigens  are  tested;  in  the immunospot  assay,  sensitization  to  one or  more antigens 
specific to only M.tuberculosis is tested. A diagrammatic explanation of the in vivo TST and in vitro 
inmmunospot assay is given below (fig 1).
Fig 1: Diagrammatic representation of in vivo and in vitro T cell based diagnostic tests  
Specific antigens of tuberculosis
During the past  decade,  a major scientific advance has been the identification of antigens that are 
expressed  by  M.tuberculosis,  but  not  by  BCG  or  by  most  environmental  bacteria.  Harboe  and 
colleagues showed the first evidence of tuberculosis complex-specific antigen [38]. They detected the 
24-kDa antigen MPB64 (also referred to as MPT64) in M bovis and M tuberculosis culture filtrates, but 
not  in those from BCG. This  observation was later  extended by PCR hybridisation studies,  which 
showed the gene encoding MPT64 to be absent only in some BCG substrains (table below) [39]. More 
recently, the early-secreted antigenic target 6-kD protein (ESAT-6) was identified from culture filtrate 
because  of  its  strong  recognition  in  animals  infected  with  M  tuberculosis  [40].  An  interspecies 
assessment showed the gene to be largely restricted to the tuberculosis complex, being absent in all 
strains of BCG and in environmental isolates with the exception of  M kansasii, M marinum, and  M 
szulgai [41,42,43].  In continuation of this work, the promoter region of the  M tuberculosis ESAT-6 
gene was cloned and another antigen designated culture filtrate protein 10 (CFP10), with the same 
species distribution as ESAT-6 was identified (next table ) [44]. 
In 1996, Stover and colleagues [45] used subtractive hybridisation to define regions of differences 
(RD)—stretches of the genome of M bovis, which were deleted in BCG during in-vitro passage. These 
regions  were  called  RD-1,  RD-2,  and  RD-3,  and  the  genes  for  ESAT-6,  CFP10,  and  MPT64 (in 
addition to a number of new potentially interesting antigens) reside in these deleted regions (figure 2). 
New studies using bacterial artificial chromosome libraries and microarray technology have identified 
at least eight more regions that have been deleted in BCG. Both ESAT-6 and CFP10 are genomic 
products of the RD1 gene.
Fig 2: Genes present in mycobacterial strains
Studies on use of ESAT-6 and CFP 10 antigens 
The ESAT-6 antigen has so far consistently been reported to be strongly recognised by IFN-γ-secreting 
lymphocytes from patients with tuberculosis. ESAT-6 evokes murine T-cell responses early during M 
tuberculosis infection  and  induces  stronger  responses  in  patients  with  tuberculosis  than  other 
mycobacterial proteins tested so far [46,47]. The percentage of ESAT-6-responsive patients ranges in 
studies done in low endemic countries (Denmark, USA, Germany, and Kuwait) from 60% to 80%, 
whereas reactivity in healthy individuals is virtually absent [46,47, 48, 49]. ESAT-6 contains multiple 
broadly recognised T-cell epitopes, so that a test based on ESAT-6 should have the potential to induce 
responses in genetically diverse populations. In this regard, Lalvani and colleagues [50] enumerated 
ESAT-6-specific T cells by an IFN- specific ELISPOT assay and found a diagnostic sensitivity of more 
than 90%; however, no response was seen in unexposed healthy donors [50].  CFP 10 is recognised in 
almost the same high frequency in patients with tuberculosis [51].
Enzyme-linked immunospot assay (ELISPOT)
Lalvani  and  colleagues  first  devised  this  test  in  patients  with  past  exposure to  influenza  virus.  A 
sensitive enzyme-linked immunospot (ELISPOT) assay for single cell IFN-γ secretion to detect low 
frequencies  of  uncultured  influenza  peptide-specific  CD8  T  lymphocytes  isolated  from peripheral 
blood was applied. The ELISPOT assay detects secreted cytokine molecules in the immediate vicinity 
of the cell from which they are derived, while still at a relatively high concentration; each spot in the 
read-out representing a ‘footprint’ of the original cytokine-producing cell. Quantitation of these IFN-γ 
spot-forming cells (SFCs) by this technique is highly sensitive. [52].    
ELISPOT assay for detection of latent M tuberculosis infection
Lalvani  et  al  used  the  enzyme  linked  immunospot  assay  for  rapid  detection  of  Mycobacterium 
tuberculosis infection by enumeration of antigen-specific T cells [53]. In vitro stimulation of human 
peripheral blood mononuclear cells (PBMCs) by the specific ESAT-6 antigen induces IFN-γ detectable 
by enzyme-linked immunosorbent assay (ELISA). Four groups were studied. Forty-five of 47 patients 
with bacteriologically confirmed tuberculosis had ESAT-6 specific IFN-γ secreting T cells, compared 
with 4 of 47 patients with nontuberculous illnesss, indicating that these T cells are an accurate marker 
of M.tuberculosis infection. This assay thus had a sensitivity of 96% (95% confidence interval 92-100) 
for detecting M.tuberculosis infection in this patient population. By comparison, of the 26 patients with 
tuberculosis who had a diagnostic TST, only 18 (69%) were positive (p=0.003). In addition, 22 of 26 
(85%)  TST-positive  exposed  household  contacts  had  ESAT-6  specific  T  cells,  whereas  0  of  26 
unexposed BCG-vaccinated subjects responded. Thus it distinguishes between M.tuberculosis infection 
and BCG vaccination. This has been further confirmed by similar studies by Lalvani et al. [54.55]. 
ELISPOT test can be used to determine prevalence of latent Mycobacterium tuberculosis infection. It 
was performed in 100 prospectively recruited healthy adults in Mumbai [60]. Eighty percent responded 
to more than or equal to one antigen. In contrast, of 40 mostly BCG-vaccinated, United Kingdom-
resident healthy adults, none responded to either antigen. This study suggests an 80% prevalence of 
latent M.tuberculosis infection in urban India.  
ELISPOT assay for detection of active M tuberculosis infection
Recently it has been shown that ESAT-6-specific IFN-γ-secreting CD4+ T cells are concentrated at sites 
of active tuberculosis [56]. Ten patients with tuberculous pleural effusion had a 15-fold concentration 
of the T cells relative to their level in peripheral blood. Such cells were absent in 8 control patients with 
nontuberculous  pleural  disease  [56].  The  recruitment  of  ESAT-6-specific  T  cells  to  inflamed 
tuberculous  tissue  demonstrates  their  function  in  vivo  and  suggests  a  novel  way  to  diagnose 
tuberculous pleuritis.   It has also been used to detect latent and active tuberculosis infection in HIV-
positive individuals, sensitivity of the test being 92% [57]. 
ELISPOT assay for diagnosis of tuberculous meningitis
Detection of functional MTB-antigen-specific T cells in CSF is scientifically challenging given the 
rapid activation-induced death of CSF T cells in tuberculous meningitis.[58]. There is no published 
data on using this test for diagnosis of tuberculous meningitis. This study was undertaken as a pilot 
study to determine whether IFN-γ-secreting MTB-antigen-specific T cells are present in the CSF of 
patients with tuberculous meningitis, whether the use of ELISPOT on CSF samples is feasible, and 
whether ELISPOT has a clinically useful diagnostic sensitivity for active tuberculous meningitis. 
MATERIALS AND METHODS
This was a prospective study carried out in the department of Neurology, Christian Medical College, 
Vellore, India, from March 2004 to May 2006. Subjects were also recruited from the departments of 
Medicine.  Subjects  were divided as cases and controls.   Cases were patients  with clinical  features 
highly suggestive of tuberculous meningitis presenting consecutively to the study physician.  Controls 
were patients with meningitis, but not of tuberculous etiology.  Following were the criteria used for 
recruitment of patients.
Inclusion criteria
Age 16 years and more 
Fever, headache or vomiting for more than 2 weeks in cases
CSF picture suggestive of meningitis
Exclusion criteria
Radiological evidence of significant brain edema and impending herniation (cannot get much CSF) 
Antituberculous medication use for more than a week 
Traumatic CSF (RBC count >1000/cmm) 
The diagnosis of tuberculous meningitis was made based on defined criteria [59].  Specific clinical 
criteria  included  fever,  headache  and  neck  stiffness  for  more  than  2  weeks.  Supporting  criteria 
consisted of 1) CSF findings of lymphocytic pleocytosis, raised protein levels and sterile cultures 2) 
CT/MRI  findings  of  hydrocephalus,  granulomas  or  basal  exudates  3)  evidence  of  extra  CNS 
tuberculosis 4) appropriate response to anti-tuberculosis chemotherapy. Patients with specific clinical 
criteria  were  classified  as  “highly  probable  tuberculosis”  if  3  supporting  criteria  are  present  or 
“probable tuberculosis” if only 2 were present. Only  “probable” and “highly probable” cases were 
included in the study.  
CSF (5ml) by lumbar puncture and heparinised peripheral venous blood (10ml) were collected 
from each of these patients at the time of the initial testing, at admission. Samples for ELISPOT assay 
were processed within 6 hours of collection. If collected overnight, they were kept in an air-conditioned 
room and sent to the lab for processing in the morning.   All  CSF samples were also subjected to 
estimation of sugar,  protein content and to microscopy of centrifuged CSF with Gram, Ziehl-Neelsen 
and India ink stains, with PCR for mycobacterium tuberculosis (using IS6110 primers), and bacterial, 
mycobacterial and fungal culture.  
The  ex-vivo  IFN-γ ELISPOT assay incorporating overlapping peptides spanning ESAT-6 and 
CFP10  was  performed  using  2.5X105 peripheral  blood  mononuclear  cells  (PBMC)  or  CSF  cells 
incubated overnight in complete medium in single wells of pre-coated interferon-γ ELISPOT plates, as 
described  below.   The  reagents  of  the  ELISPOT  assay  were  obtained  from  the  Tuberculosis 
Immunology Group, Nuffield Department of Medicine, University of Oxford.
Methodology of performing the MTB ELISPOT assay [60]
Add 100µl per well of R10 medium is added into the ELISPOT wells and placed in the incubator at 
370C for 1 hour.
Collect  10ml  of  whole  blood in  a  50ml  centrifuge  tube  containing  25µl  of  heparin  (Heparin  at  a 
concentration of 5000U/ml).
Dilute the entire 10 ml of whole blood with 8 ml of RPMI1640 medium.
Gently layer 9ml of whole blood onto 5ml of Ficoll in a 15 ml Falcon tube.
Turn brake off and spin blood at 2000 rpm for 22minutes.
Transfer 2ml of the separated plasma and transfer into a clean 15ml Falcon tube and then add PBMC 
layer.
Bring up to 12ml with R10 medium.
Spin cells at 1700rpm for 7 minutes.
Remove supernatant from cells.
Gently resuspend pellet in R10.
Make up to 10ml with R10.
Mix and remove 10µl for counting chamber.
Spin at 1350 rpm for 7 minutes.
Resuspend pellets such that there are 2.5x 106 cells per ml.
Add 50µl “positive control” (PHA – phytoheamagglutinin), “panel A” (ESAT-6 pool) and “panel B” 
(CFP-10 pool) to appropriate wells. Add nothing to negative control. 
Incubate the wells overnight at 370C in a 5%CO2 incubator.
Wash 6 times with 150µl per well of PBS-Tween20 buffer. Tap on paper towels to remove remaining 
liquid.
Add secondary antibody at 1µgm per well. Dilute it in PBS. Add 50ul per well. (5µl per ml of PBS).
Incubate at room temperature for 90 minutes.
Wash 6 times with 150µl per well of PBS-Tween 20 buffer and tap plate on paper towels to remove 
remaining liquid.
Add 50µl per well of BCIP chromogen and allow spots to develop at room temperature for 20 minutes.
Once the spots are clearly seen in the wells containing PHA stop the reaction by washing the wells in 
tap water 3 times.
Procedure for processing CSF
Spin CSF in a centrifuge tube at 1500rpm for 10 minutes in a refrigerated centrifuge.
Remove supernatant using a pipette tip (Do not decant by tipping the tube, use only 200µl pipette). The 
cell pellet is usually not seen.
Resuspend cell pellet (invisible) in 5ml of RPMI1640.
Take out 10µl for counting.
Spin the suspended cells at 1200rpm for 5minutes.
Determine the amount  of R10 to  be used for final  suspension of the cells  by counting,  while  the 
spinning is going on.
Resuspend the cell pellet obtained in the determined amount of R10.
Add 100µl of the cell suspension into the 4 wells.
A worksheet is prepared as follows.
250,000 cells in 
RPMI 1640 10% 
250,000 cells RPMI 
1640 10% FCS + 50µl 
of PHA “positive 
control”
250,000 cells in RPMI 1640 
10% FCS + 50µl of  CFP-10 
pool “Panel B” 
250,000 cells in RPMI 1640 
10% FCS + 50µl of  ESAT-6 
pool “Panel A” 
RPMI – Roswell Park Memorial Institute (Nutritive liquid medium), 
FCS – Fetal calf serum (Nutritive liquid medium)
PHA – Phytohemagglutinin, 
ESAT-6 – Early secretory antigen 6, 
CFP 10 – Culture filtrate protein 10
Well 1 – negative control
Well 2 – positive control
Well 3 – contains ESAT-6 antigen
Well 4 – contains CFP 10 antigen 
Procedure for counting cells
Dilute 10µl of the cell suspension in 90µl of 1XPBS. After mixing thoroughly, take 10µl of the cell 
suspension and place it on the counting grid of the hemocytometer.
Count the total number of cells in the four outer large squares.
Average number of cells = Total number of cells counted in the 4 squares
Total cell count = Average number of cells x104x10 (dilution factor) x volume from which the initial 
10µl for cell counting is drawn (This may be 5ml in the case of CSF or 10 ml in the case of whole 
blood).
Adjust the cell concentration such that there are 250,000 cells in every 100µl. 
Spot counting 
ELISPOT plates were scored by eye, using a hand lens. Thresholds for a positive response were more 
than 5 (for peptides) or 10 (for phytohemagglutinin (PHA): positive control) spot forming cells (SFCs) 
and at least twice the frequency of, the negative control wells, as previously described [6, 9]. 
Background numbers of SFC in negative control wells were always ≤5/well. The person performing 
and reading the assays was blind to personal identifiers and clinical and microbiological data. The test 
was carried out in the Nephrology diagnostics lab of Christian Medical Hospital by the technologist 
posted there. 
The clinician (myself) blind to the results of ELISPOT assays prospectively assessed case records of 
each patient on a proforma.
Sensitivity and confidence intervals were calculated using a statistical package SPSS.
RESULTS
During the study period, a total of 24 patients were recruited, the number of the cases being 14 and 10 
controls. The age and sex distribution of the subjects is as given in table 1 and 2 respectively.
Table 1. Age distribution of cases and controls
Age (years) CASES (n=14) CONTROLS (n=10)
Mean 39.6 yrs 42.8 yrs
Median 37 yrs 42 yrs
Range 16 – 69 yrs 15 – 73 yrs
SD 39.6 ± 15.4 42.8 ± 20.1
Table 2. Sex distribution of cases and controls
Sex CASES CONTROLS
Male 8 (57.1%) 9 (90%)
Female 6 (42.8%) 1 (10%)
Total 14 10
Table 3. Clinical Diagnosis in cases and controls
Diagnosis Number Percentage
CASES (n=14)
Highly probable TBM 8 57.1%
Probable TBM 6 42.8%
CONTROL (n=10)
Partially treated 
pyogenic meningitis
5 50%
Aseptic meningitis 3 30%
Carcinomatous 
meningitis
2 20%
Out  of  the  14  cases  of  tuberculous  meningitis,  8  were  diagnosed  as  ‘highly  probable’  and  6  as 
‘probable’.  None of  them were  confirmed cases  as  none  had  bacteriologically  proven tuberculous 
meningitis.
The duration of clinical symptoms in all the cases was more than 2 weeks. In the controls, the duration 
ranged  from 2  days  to  4  months,  the  longest  duration  being  for  the  patient  with  carcinomatous 
meningitis. 
Table 4. Clinical symptoms in cases and controls
Symptoms CASES (n=14) CONTROLS (n=10)
Fever 8 (57.1%) 7 (70%)
Headache 11 (78.5%) 4 (40%)
Vomiting 6 (42.8%) 3 (30%)
Seizures 3 (21.4%) 1 (10%)
Altered sensorium 3 (21.4%) 6 (60%)
Visual disturbance 6 (42.8%) 0
 
Table 5. Clinical signs in cases and controls
Signs CASES (n=14) CONTROLS (n=10)
Neck stiffness 3 (21.4%) 6 (60%)
Papilledema 4 (28.5%) 1 (10%)
Cranial nerve 3,4, 6 palsy 6 (42.8%) 1 (10%)
Other cranial N palsy 2 (14.2%) 0
Hemi/Quadriparesis 0 2 (20%)
Paraparesis 2 (14.2%) 0
Cerebellar signs 1 (7.1%) 0
Extra CNS TB 3 (21.4%) 0
The commonest presenting symptoms in both cases and controls were fever and headache. The controls 
were more sick at admission, 6 (60%) of them being in altered sensorium as compared to the cases 
where only 3 (21.4%) of them were in coma. Only 3 of the cases had close contact with tuberculosis 
either within the household or within the work place.  
Table 6. Peripheral blood total white cell count in cases and controls.
Total White cell count 
per cu mm
CASES (n=14) CONTROLS (n=10)
>15,000 0 3 (30%)
<15,000 14 (100%) 7 (70%)
Total white cell count is one of the variables used in the diagnostic score for clinical diagnosis of 
tuberculous meningitis. All cases had total white cell count less than 15 000 as one expected.  The 3 
controls that had high white cell count were those with pyogenic meningitis.   
Table 7. Cerebrospinal fluid variables in cases and controls   
CSF variable CASES (n=14)
Median (90% range)
CONTROL (n=10)
Median (90% range)
Total WCC (per ml) 115 (2 – 750) 200 (30 – 6400)
% Lymphocytes 97 (65 – 100) 95 (40 – 99)
CSF/ blood glucose ratio 0.4 (0.2 – 0.57) 0.49 (0.1 – 0.89)
CSF protein (mg/ml) 159 (21- 900) 104 (49 – 450)
WCC – white cell count
All  cases  except  one  had  CSF  pleocytosis  more  than  750  per  cu  mm  and  all  had  lymphocytic 
predominance.  Even among the controls,  only 3 (30%) had very high CSF count,  as  most  of  the 
controls were partially treated pyogenic meningitis. CSF glucose to blood glucose was low in most of 
the cases (78%). CSF protein was high in all cases.
Culture and PCR results
Routine cultures for all cases and controls showed no growth. CSF for AFB smear and culture were 
negative in all cases. 
TB PCR on CSF was positive only in one patient; however, the ELISPOT test in the same patient was 
negative due to low CSF cell count. In the rest of the cases, TB PCR was negative.
Table 8.  Chest X ray in cases and controls
Chest X ray CASES (n=14) CONTROLS (n=10)
Normal 10 (71.3%) 8 (80%)
Abnormal 4 (28.5%) 2 (20%)
Only 4 cases (28.5%) had chest X ray evidence of tuberculosis in the form of pleural effusion, perihilar 
lymphadenopathy and apical opacities. On the other hand, 20% of the controls also had abnormal chest 
X ray that was suggestive of aspiration pneumonia.  
Table 9. Neuroradiology in cases and controls
CT/MRI Brain CASES (n=14) CONTROLS (n=10)
Normal 6 (42.8%) 8 (80%)
Abnormal 8 (57.2%) 2 (20%)
Table 10. Abnormal Neuroradiology findings in cases
Abnormality Number (total =14) Percentage
Tuberculoma 1 7.1%
Spinal arachnoiditis 1 7.1%
Vertebral disc disease 1 7.1%
Cord myelitis 1 7.1%
Meningeal enhancement 3 21.4%
Cortical venous sinus 
thrombosis
1 7.1%
Infarcts 1 7.1%
Hydrocephalus 1 7.1%
All patients in the study had either CT or MRI of the brain prior to performing the CSF analysis. The 
various  MRI  abnormalities  present  were  meningeal  enhancement  on  post  contrast  scan  (21.4%); 
tuberculomas (7.1%) and one patient had multiple infarcts (7.1%). Some of the abnormal MRI findings 
are shown.
Image 1. T1 W post contrast axial MRI brain images showing multiple confluent ring enhancing 
lesions in trigonal region of left ventricle with minimal subependymal and parenchymal extension with 
extensive edema. 
                                                         
 
                    
                                             
Image 2. T1 W post contrast axial MRI brain images of the above patient on treatment with ATT 
showing confluent thick walled, ring-enhancing lesions predominantly centered in the right thalamus. 
Enhancement of the ependyma and the choroid plexus of the left lateral ventricle compared to the last 
MRI has  totally resolved.  Appearance  of  new tuberculomas  while  on treatment  with  ATT is  well 
known.
                                                             
          
Image 3. T1 W post contrast sagittal images of MRI brain showing diffuse thickening and 
enhancement of the tentorium, falx cerebelli, dura along the floor of posterior cranial fossa, petrous 
apex and parasellar regions. 
Image 4. T1 W post contrast sagittal images of MRI brain of the above patient post treatment with 
antituberculous chemotherapy showing complete resolution of the meningeal enhancement.
Image 5. T2 W and T1 W post contrast MRI brain axial images showing wedge shaped area of altered 
signal intensity (hypo in T1 and hyper in T2) in the right frontal lobe involving the inferior frontal 
gyrus and adjacent  white  matter  with no post  contrast  enhancement,  mild adjacent  leptomeningeal 
enhancement and mild mass effect suggestive of subacute infarct due to tuberculous arteritis.
         
Table 11. ELISPOT ASSAY in cases and controls
Test CASES (n=14) CONTROLS (n=10)
Positive in blood only 3 2
Positive in CSF only 1 0
Positive in CSF & 
Blood
6 0
Negative in CSF & 
Blood
2 7
Failed assay 2 1
Low CSF counts in 4 cases.
Only 8 cases were ideal for both CSF and blood analysis for the ELISPOT assay. Out of these 8 cases, 
6 were positive in both blood and CSF and one only in CSF. 
In two of the 14 cases, the assay failed, i.e., the positive control also showed no response, indicating 
that the lymphocytes isolated were not viable and did not react with phytohemagglutinin. One of them 
had received steroids prior to the assay and this could probably have caused lymphocytes to degenerate. 
There were no identifiable reasons for the other case having failed. Three of the 14 cases that were 
positive in blood but negative in CSF had low CSF cell count (less than 25 cells per cu mm) and hence 
enough lymphocytes could not be isolated. One of the case that was negative in CSF and blood also 
had low CSF cell count. Thus 4 cases had negative CSF due to low CSF white cell count (white cell 
count below 25).
Among the controls, one of the assays was invalid both for blood and CSF. The CSF assay probably 
failed  as  there  was  contamination  of  the  CSF  with  blood  and  blood  is  known  to  interfere  with 
lymphocyte viability. All controls had enough CSF cell count for adequate lymphocyte separation. CSF 
was negative in the 9 controls. The test was positive in blood only in 2 controls, which could mean that 
the person had been exposed to the tuberculous antigen and need not necessarily mean infection. Both 
these controls were not exposed to BCG vaccine.
 The sensitivity of the test calculated was 87.5% and specificity 100% with positive predictive value of 
100% and negative predictive value 90%. The significance calculated by the Fischer exact test was 
0.00041, this being highly significant. 
Image 6. ELISPOT wells showing negative results for CSF and blood
The top 4 wells are for CSF and the lower 4 wells for blood. The 1st well has the negative control, the 
2nd positive control and the 3rd and 4th wells has the specific peptides (ESAT-6 and CFP10 respectively). 
Here the positive control is showing spots and not the other wells, indicating that T cells are viable but 
not reactive for the TB peptides. 
Images 7 & 8. Image 7 shows ELISPOT assay being positive for blood and negative for CSF. Image 8 
shows the assay being positive for blood and CSF.
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DISCUSSION
Tuberculosis is a disease of increasing significance. Tuberculous meningitis is the most serious form of 
tuberculosis and needs to be attended to as a medical emergency. Delay in diagnosis and treatment are 
regarded as the major contributing factors in the high mortality. Despite chemotherapy, it is fatal in 
25% of adults  and causes neurological sequelae in  25% of survivors [1].   Delay in  diagnosis  and 
treatment are regarded as the major contributing factors in the high mortality.
The initial diagnosis of tuberculous meningitis is based on the neurological symptoms, signs and CSF 
analysis. Various diagnostic criteria have evolved [22, 23] because of the lack of a sensitive test for 
confirmation of tuberculous meningitis. Definitive diagnosis is based on isolation of mycobacterium 
from the CSF. However this being a paucibacillary form of tuberculosis, demonstration of AFB in CSF 
in patients with tuberculous meningitis  is less than 20%. A recent study reported a bacteriological 
diagnosis of tuberculous meningitis in 107 (81%) of 132 adults with the disease; acid-fast bacilli were 
seen in 77 (58%) patients, and cultured from 94 (71%) patients [27]. They recommend that at least 6 ml 
of CSF should be collected and examined for 30 minutes to improve the yield.  A microbiological 
confirmation could not be obtained in any of our patients. 
This  pilot  study was undertaken to  determine the feasibility of a  T cell  based assay for the rapid 
diagnosis of tuberculous meningitis.
The  test  was  performed  in  14  cases  with  tuberculous  meningitis  -  diagnosis  based  on  standard 
diagnostic  criteria  [60]  and 10 patients  with non-tuberculous  meningitis  that  served as  the  control 
samples.  All  cases  were  classified  as  having  either  ‘highly  probable’  or  ‘probable’  tuberculous 
meningitis. All of them had responded to anti tuberculous chemotherapy at follow up except for one 
patient who had shown response in the initial month of chemotherapy and then was lost to follow up. 
The controls included patients  with partially treated pyogenic meningitis (50%), aseptic meningitis 
(30%) and carcinomatous meningitis (20%). Three of them died, 2 with the carcinomatous meningitis 
and one with pyogenic meningitis who was elderly (73yrs) and also had multiorgan failure. The rest of 
the  control  subjects  improved during  the  hospital  stay itself  with standard treatment  based on the 
diagnosis. 
The median age of the patients with tuberculous meningitis was 37 years and the mean was 39.6 years. 
Tuberculous meningitis is classically described as a disease of the young adults, which is in keeping 
with this study. In the diagnostic criteria for diagnosis of tuberculous meningitis devised by Thwaites et 
al [23], the cut off age for likelihood of tuberculous meningitis is below 36 years. Majority of our 
patients were males.
Only ‘highly probable’ (n = 8; 57.1%) and ‘probable cases’ (n = 6; 42.8%) of tuberculous meningitis 
were included in the study.   The control  subjects  clearly had no clinical  evidence for tuberculous 
meningitis. 
The commonest clinical symptom for patients with tuberculous meningitis was headache (78.5%). The 
other symptoms were fever (57.1%), visual disturbances (42.8%) in the form of blurring of vision, 
diplopia,  photophobia  and  vomiting  (42.8%).  This  is  in  keeping  with  studies  from other  centers 
[15,16,19] where headache and fever were the most common presenting symptoms (50 to 80%).
The commonest  clinical  sign was focal  neurological  deficits  (78.3%) in  the form of  cranial  nerve 
palsies, paraparesis (due to tuberculous myelitis) and cerebellar signs. Only 21.4% of cases had neck 
stiffness. Other studies show that the presence of neck stiffness ranged from 40 to 80% [15]. 
Only 3 cases (21.4%) had evidence of extra CNS tuberculosis - pulmonary tuberculosis in 2 and Pott’s 
spine in the other. Extra CNS tuberculosis has been found in about 10 - 22% of non HIV- infected 
patients with tuberculous meningitis [22] but on the other hand, HIV- infected patients presenting with 
tuberculous meningitis have 41 – 68 % incidence of extra CNS tuberculosis [61].
The CSF abnormality in patients with tuberculous meningitis showed pleocytosis (median being 115 
cells per ml) with lymphocyte predominance (median 97%), low CSF glucose to blood glucose ratio 
(median 0.4) and high protein (median 159 mg per dl). One patient had normal CSF despite the MRI 
showing pachymeningitis. CSF pleocytosis with lymphocyte predominance and low CSF glucose to 
blood  glucose  ratio  are  two  important  variables  in  the  clinical  diagnostic  criteria  for  tuberculous 
meningitis  [22,23].  CSF  analysis  thus  forms  an  important  aspect  in  the  diagnosis  of  tuberculous 
meningitis. However, in certain forms of CNS tuberculosis as in tuberculomas, CSF may be normal. It 
is in these situations that diagnosis becomes difficult unless one opts for tissue diagnosis, which is very 
invasive.  
We were unable to obtain microbiological confirmation of TB in any of our patients. This was not 
surprising, as this is a paucibacillary form of TB in which microbiological confirmation is frequently 
not obtained, especially in the setting of a routine service laboratory. A bacteriological gold standard is 
too insensitive to be used alone for evaluation of new diagnostic tests, which may be more sensitive 
than culture and Ziehl-Neelsen [23]. Therefore, like other investigators[22,23,59] we used composite 
reference standards for diagnosis that use culture, Ziehl-Neelsen, clinical, radiological and therapeutic 
outcome criteria. 
All cases had either CT or MRI of the brain with contrast. It was abnormal in 57.2% (n=6) of the cases 
while in the controls it was abnormal in 20% (n=2).  Other studies report abnormality on neuroimaging 
in 68 – 80 %. Since the findings are non-specific, radiology alone cannot be relied on for the diagnosis 
of tuberculous meningitis. However it forms a reliable supporting evidence for diagnosing the disease. 
The abnormal  imagings in  the controls  were for the patient  with post  trauma meningitis  who had 
fracture of the left maxillary sinus and frontal bone. The other abnormal imaging was for the patient 
with carcinomatous meningitis with multiple cranial nerve palsies. 
T cell based assays have been used for diagnosis of latent tuberculous infection [54,55,60] and also in 
active tuberculous infection [56].  Recently it has been shown that ESAT-6-specific IFN-γ-secreting 
CD4+ T cells are concentrated at sites of active tuberculosis [56]. Using ELISPOT these cells can be 
detected in pleural fluid [56], suggesting that this assay may be a rapid, sensitive and specific marker 
for active TB at specific anatomical sites. 
This  pilot  study  done  showed  the  presence  of  interferon  γ-secreting  Mycobacterium  tuberculous 
antigen-specific T cells in the cerebrospinal fluid of patients with tuberculous meningitis  using the 
enzyme linked ELISPOT assay.  Further,  these cells  were absent  in the CSF of patients  with non-
tuberculous meningitis. The ELISPOT assay for diagnosis of tuberculous meningitis, as per this study, 
showed a high diagnostic sensitivity of 87.5%, specificity of 100% with positive predictive value of 
100% and negative predictive value 90%.   The high sensitivity and speed of CSF ELISPOT suggest it 
could be a useful tool for diagnosis of patients with suspected tuberculous meningitis. However in 
cases with suboptimal cell numbers (<250,000/well), assay sensitivity is adversely affected.  Notably, 
cell numbers were suboptimal in 4 of the 5 negative CSF assays, suggesting low cell numbers are 
associated with failure of the assay. None of the control samples were positive in CSF though 2 of them 
were positive in blood. 
There was general concordance of assay results between peripheral blood mononuclear cells (PBMC) 
and CSF, with the exception of one case in which CSF alone was positive. Frequencies of responding 
cells were equivalent in PBMC and CSF (p=0.865 Wilcoxon signed rank for difference), in contrast to 
the increased concentration of MTB-antigen-specific T cells at the site of disease in pleural TB[9].
The difficulties encountered with the assay were:
1) Necessity for large volume of CSF (at least 5 ml required), which may be difficult to obtain in the 
setting of raised intracranial tension when sample is also required for other CSF tests.  
2) Since this is a test on live cells, the sample has to be preserved carefully and processed as fast as 
possible within 6 hours of the CSF collection. This may be difficult when CSF collection is carried 
out in the late hours of the day and night when the labs may not be accessible. 
3)  Isolation  of  the  lymphocytes  requires  expertise  and many labs  may not  have  this  facility.  It 
requires a minimum period of 6 hours of the technologist to carry out one assay. 
4)  Low CSF cell count as in the case of tuberculomas and contamination of CSF with blood as in the 
case of a traumatic tap renders the test insensitive. 
This  study  has  demonstrated  that  ELISPOT  is  a  potential  new  diagnostic  test  for  tuberculous 
meningitis, which is rapid, practicable in a resource-poor setting, and appears to have high sensitivity. 
Large prospective studies are now warranted to validate the clinical utility of CSF ELISPOT in routine 
practice. Such studies should have better microbiological confirmation, should include children and 
more controls to obtain robust estimates of the diagnostic specificity as well as sensitivity. 
CONCLUSIONS
• This  study used  a  T cell  based  assay (Enzyme linked immunospot  assay –  ELISPOT)  for 
diagnosis of tuberculous meningitis. The assay has demonstrated presence of ESAT-6 and CFP 
10 specific IFN-γ-secreting CD4+ T cells in the cerebrospinal fluid of patients with tuberculous 
meningitis.
• The assay was used for diagnosis of tuberculous meningitis. It is a rapid test with the result 
being available in 24hours. The test has a high diagnostic sensitivity of 87.5% and specificity of 
100% with positive predictive value of 100% and negative predictive value 90%.   
• The limitations of the assay include necessity for large volume of CSF for the test, careful and 
quick processing of the CSF sample, lymphocyte isolation from blood and CSF requires 
expertise, and presence of blood in CSF and low CSF cell count renders the test insensitive. 
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Objectives:  To evaluate usefulness of the enzyme linked immunospot assay (ELISPOT),  a T cell 
based  assay  using  specific  Mycobacterium  tuberculosis antigens,  ESAT-6  and  CFP  10,  for  the 
diagnosis of tuberculous meningitis.
Methods: This was a prospective study carried out in the department of Neurology, Christian Medical 
College & Hospital, Vellore, India, from March 2004 to May 2006. Cases were adult patients with 
clinical features highly suggestive of tuberculous meningitis; controls were age-matched patients with 
meningitis  of  non-tuberculous  etiology.   ELISPOT assay was  performed  on  CSF and  heparinised 
peripheral venous blood. The results were analysed for specificity and sensitivity of the test.
Results:  A total  of  14  cases  and  10  controls  were  recruited.  Out  of  the  14  cases  of  tuberculous 
meningitis, 8 were diagnosed as ‘highly probable’ and 6 as ‘probable’. CSF for AFB smear and culture 
were negative in all cases. TB PCR on CSF was positive only in one patient. ELISPOT assay in 2 of 
the cases and one control failed. In the rest 12 cases, it was positive in CSF and blood in 6 and only in 
CSF in 1. Three cases that were positive in blood and negative in CSF had low cell count. Only 8 cases 
were ideal for both CSF and blood analysis for the ELISPOT assay and of this 7 were positive. CSF 
was negative in the 9 controls. The sensitivity of the test was 87.5% and specificity 100% with positive 
predictive value of 100% and negative predictive value 90%. 
Conclusions:  The  enzyme-linked  immunospot  assay for  detection  of  Mycobacterium  tuberculosis-
antigen-specific  interferon-γ-secreting  T cells  in  cerebrospinal  fluid from patients  with tuberculous 
meningitis had a diagnostic sensitivity of 87.5% and specificity 100%.  This pilot study demonstrates 
that this new T cell-based assay is a promising diagnostic test for tuberculous meningitis that is rapid 
and sensitive.
